How Do You Tell Whether a Breast Cancer is HER2 Positive? Ongoing Studies Keep Debate in High Gear
Open Access
- 29 December 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 103 (2) , 87-89
- https://doi.org/10.1093/jnci/djq557
Abstract
More than a decade after the drug trastuzumab (Herceptin) won approval in 1998, scientists still disagree over how to identify breast cancer patients for treatment. Trastuzumab targets human HER2, which contributes to poor outcomes in breast cancer when amplified. HER2-positive cases account for up to 20% of all newly diagnosed breast cancers, and there is no argument about trastuzumab's efficacy in these cases.Keywords
This publication has 0 references indexed in Scilit: